XXII
$1.98
22nd Century Group
($.21)
(9.59%)
XXII
Earnings Whisper ®
N/A
3rd Quarter September 2025
Consensus:  $0.00
Revenue:  N/A
Thursday
Nov 13
6:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when XXII reports earnings?
Beat
Meet
Miss

Where is XXII's stock price going from here?
Up
Flat
Down
Stock chart of XXII
Analysts
Summary of analysts' recommendations for XXII
Score
Grade
Pivots
Resistance
$2.28
$2.22
$2.10

$2.04

Support
$1.92
$1.86
$1.74
Tweet
Growth
Description
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.